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B cells are efficient antigen-presenting cells (APCs), relying on antigen uptake through the
B cell receptor (BCR). The mechanism of antigen recognition remains a topic of debate;
while the prevalent view holds that antigens need to be multivalent for BCR activation,
monovalent antigens can also initiate B cell responses. In this review, we describe the
steps required for antigen uptake, processing, and loading of peptides onto MHC Class II
compartments in B cells for efficient presentation to CD4 T cells, with a special focus in
the initial steps of BCR recognition of antigen.
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B CELLS AS ANTIGEN-PRESENTING CELLS
Professional antigen-presenting cells (APCs) take up anti-
gen through phagocytosis, fluid-phase pinocytosis, or receptor-
mediated endocytosis for processing, loading of the digestion
products onto MHC Class II (MHC II) and presentation to CD4
T cells. The ability of B cells to present antigen to CD4 T cells
was recognized over three decades ago, but they were deemed less
efficient than dendritic cells or macrophages due to their com-
paratively lower capacity to take up antigen non-specifically. In
contrast, antigen recognition through the BCR is a far better (up
to 10,000-fold) means to present antigen to CD4 T cells compared
to non-specific antigen uptake (1). BCR ligation by antigen leads
not only to antigen capture and antigen delivery to MHCII com-
partments, but also initiates signaling and de novo gene expression.
This, in turn, influences the activation state of the B cells and their
ability to engage CD4 T cell help. The nature of the antigen and
strength of interaction (affinity) for BCR are thus essential features
that determine whether processed antigen can be efficiently pre-
sented to CD4 T cells. Here, we review the sequential steps required
for BCR recognition of antigen, internalization, processing, and
loading onto MHC II, with special emphasis on the early events of
BCR–antigen interaction required for efficient B cell activation.
ANTIGEN CAPTURE BY B CELLS
Antigen recognition by naïve circulating B cells occurs in follicles
present in peripheral lymphoid organs (lymph nodes and spleen),
which receive continuous inputs by means of lymphatic fluid
originating in peripheral tissues and delivered to lymph nodes
through the afferent vessels (lymph node) or via blood, which
carries lymphocytes and antigen through the trabecular artery
(spleen) (2). Small, soluble antigens (<70 kDa) quickly (within
2 h) reach follicular B cells through conduits that penetrate the
follicle (3); larger antigens such as viruses or immune complexes
(ICs) are retained within the subcapsular sinus by macrophages
and follicular dendritic cells (FDCs) that capture and present
antigen to B cells by tethering via complement (CD21 and CD35)
or Fcγ receptors (4–6). Antigen presented on the cell surface is
recognized by the BCR through the formation of a macromole-
cular cluster of defined composition, the immunological synapse
(IS) (7). At the IS, B cells recruit and secrete MHC II-positive lyso-
somes in a microtubule-dependent polarized fashion. The small
GTPase Cdc42 is required for lysosome exocytosis, which results
in acidification of the IS extracellular space and may facilitate
removal of antigen from the presenting cell and/or proteolysis (8).
The cellular contacts between APCs and B cells last 20–30 min
(9), a timeframe that allows sustained BCR signaling and antigen
capture. Antigen is captured by BCR in a process that also brings
in membrane components by physical extraction from the pre-
senting cells (7). The efficiency of this process is the result of the
affinity of BCR–antigen interaction: stronger binders will be more
likely to be “pulled” through mechanical forces by the B cell (10).
Higher affinity for antigen also translates into enhanced CD4 T
cell activation (11). Upon antigen internalization, cognate B cells
migrate to the boundary of the B and T cell zones, aided by recog-
nition of CCL19 and CCL21 [secreted by stromal T cells (12)]
through the CC chemokine receptor 7 (CCR7) for recruitment
of T cell help. Successful engagement of CD4 T cells can lead to
formation of germinal centers (GCs), where affinity maturation
and isotype switching occur. In the process of migration, B cells
that have internalized antigen need to digest it and load the result-
ing peptides onto MHC II molecules for presentation to CD4 T
cells. How does BCR recognition of antigen permit antigen uptake,
processing, and presentation on MHC II?
EARLY EVENTS OF BCR RECOGNITION OF ANTIGEN
The BCR discriminates tonic signals delivered to B cells in their
resting state, required for survival, from activating signals that lead
to differentiation and antibody production. It is generally accepted

























































Avalos and Ploegh Early events of BCR recognition of antigen
that antigen binding leads to BCR clustering and internalization
of antigen; however, the steps required to achieve such clustering,
the antigen valency, and even whether clustering is required at
all for activation remains controversial. Total internal reflection
fluorescence microscopy suggests that most BCRs are monomeric
on the cell surface and aggregate upon ligand binding (13) in
a manner dependent on the Cµ4 domain of BCR (14). How-
ever, studies on insect cells reconstituted with the BCR complex
indicate that BCRs are oligomeric and autoinhibited complexes at
rest; upon ligand binding they undergo a conformational change
to a monomeric “active” state (15). Indeed, IgD and IgM were
found to form clusters on the surface of resting cells, though their
nanoscale organization remained mostly unaltered upon antigen
binding unless the BCR was heavily crosslinked using anti-Ig com-
plexes (16). Thus, the BCR may be distributed on the cell surface
in equilibrium between clusters of different size and number, ver-
sus monomers, and aggregation may not be a strict requirement
for activation. Such distribution may allow tonic BCR signals
necessary for survival.
Diffusion of the BCR in resting cells is constrained by the actin
cytoskeleton: areas rich in actin and the ezrin–radixin–moesin
(ERM) family of proteins, which are proteins that link plasma
membrane components to the actin cytoskeleton, are associated
with slow-diffusing BCRs. Alteration of the actin cytoskeleton by
exposure of B cells to depolymerizing agents such as Latrunculin A
or Cytochalasin D leads to BCR signaling in the absence of antigen,
and increase the rate of diffusion of the BCR (17). The tetraspanin
CD81 is required for BCR signaling upon actin disruption and
antigen binding (16). Actin plays an essential role in antigen
capture; upon antigen encounter, B cells undergo a spreading
response, presumably to help capture more antigen at those loca-
tions where actin depolymerizes and BCRs diffuse more rapidly.
This response is followed by a contraction response, clustering of
BCRs and antigen, and actin polymerization. Both spreading and
contraction responses depend on signaling-competent BCRs (18).
Thus, the actin cytoskeleton helps control BCR dynamics, both at
rest and upon activation.
The nature of antigen is critical in determining the different
steps of B cell activation. The current view that antigen needs
to be multivalent in order to crosslink the BCR (19) has been
challenged by a few studies that show that monovalent engage-
ment of the BCR can elicit B cell activation (20–22). Indeed,
antigens that are unable to simply crosslink the BCR have the
ability of activating B cells (23). One of the few reports that have
correlated the valency of antigen with outcome of B cell activa-
tion used the Hen Egg Lysozyme (HEL) BCR transgenic model
(24). HEL crosslinked chemically and then resolved by size exclu-
sion chromatography was used to obtain dimers, trimers, and
tetramers, which were then compared with HEL monomers for
their ability to activate B cells. While HEL monomers and multi-
mers elicited comparable early BCR signaling events, monomers
were less efficient at presenting antigen to cognate CD4 T cells (20).
Another study used the hapten nitro-iodophenol (NIP)-specific
B1–8 mouse and 8–12 residue peptides bearing different numbers
of NIP linked to the ε-amine of lysine residue incorporated into
the peptide. Peptides bearing low numbers of NIP (two and three)
molecules could activate B cells as read out by tyrosine phospho-
rylation and Ca2+ flux, but did so inefficiently, while monomers
failed to induce any response. Surprisingly, dimers could activate
equally well, regardless of whether NIP-molecules were placed on
adjacent lysines or whether separated by 24 amino acids, a find-
ing difficult to reconcile with the expected molecular distances
between variable regions in the same BCR or achievable upon
clustering (21). The question of antigen valency has been difficult
to address because the existing transgenic BCR models are spe-
cific for molecules whose valency cannot be carefully controlled
in vitro: DNA is a multivalent antigen with a repetitive struc-
ture, and it is technically challenging to demonstrate the absence
of protein aggregates in solution. While free hapten can bind to
an antibody of the appropriate structure, free hapten does not
activate B cells; for immunization, haptens require association to
carrier molecules where the position of the hapten on the car-
rier is not known and in any case is highly variable (24–26). In
an attempt to answer the question of valency required for activa-
tion of antigen specific B cells, we resorted to transnuclear mice
specific for ovalbumin (OVA) for which the peptide epitope was
mapped to the 10-amino acid peptide DKLPGFGDSI in which the
FGD sequence is essential for recognition (27). A 17-mer peptide
centered on the FGD epitope promoted early BCR responses as
strongly as did OVA (Figure 1A). Shorter peptides still bearing
FIGURE 1 | Monomeric antigen can induce BCR cross-linking and
activation as long as a signaling threshold is attained. (A) OB1 B cells
bear a BCR specific for ovalbumin (OVA), and activation and cross-linking is
produced upon interaction with a 17-mer peptide containing the OB1 epitope
and an essential FGD sequence. As the size of the peptide including the FGD
sequence decreases, so does the ability to induce signal: an 8-mer peptide
fails to produce above-threshold signals and it is suboptimal; a 4-mer peptide
(GFGD) fails to induce any signal. (B) Reagents directed to the constant
region of IgG (such as anti-IgG or anti-kappa) cross-link the BCR by bringing
BCRs in close apposition, a similar effect is produced upon chemical
conjugation of 8-mer to produce dimers that can now induce significant
(above-threshold) BCR signaling.

























































Avalos and Ploegh Early events of BCR recognition of antigen
the FGD epitope progressively lost the ability to activate B cells,
with an 8-mer version yielding suboptimal signals and a 4-mer
version being inert (Figure 1A). Monovalent peptide promoted
expression of CD86 activation marker, but less so than that evoked
by the natural ligand, OVA. In unstimulated OB1 B cells, most
IgG BCR remained monomeric, and 17-mer-peptide incubation
lead to clustering of the BCR, internalization and localization
to MHC II compartments (22). Thus, monovalent antigens can
trigger BCR responses but only when early signals may exceed a
threshold required to elicit BCR optimal downstream signaling
and expression of activation markers, leading to BCR clustering
(Figure 1A). Less efficient monovalent antigens can bind and trig-
ger proximal BCR events but the signal may not be of sufficient
duration or strength to elicit activation marker expression. Agents
capable of crosslinking the BCR and commonly used to activate
polyclonal B cells [such as the widely used F(ab)′2 anti-IgM] may
simply “bypass” the specificity threshold barrier by enforcing close
apposition of BCRs (Figure 1B). Indeed, by chemically conjugat-
ing 8-mer (suboptimal) peptides, we were able to create optimal
responses (Figure 1B). Thus, upon BCR ligation two types of sig-
nals may emerge that depend on the valency of antigen and the
physical disposition (clustered or free) of the BCR; monovalent
antigen may trigger a signal that needs to overcome a threshold
to start the activation process and clustering, and polyvalent anti-
gen may ligate already clustered BCRs and/or bring BCRs closely
together. Monovalent membrane-bound antigens are more effi-
cient at triggering BCR signals and at antigen presentation to CD4
T cells when compared to their soluble counterparts, possibly due
to a high local concentration of antigen in the two-dimensional
structure of the IS (7). Perhaps monovalent BCR engagement may
be more prevalent for membrane-bound antigens though soluble
monovalent antigens can mediate activation as well.
BCR SIGNALING AND ANTIGEN INTERNALIZATION
Upon antigen recognition by the BCR, the kinase Lyn phospho-
rylates immunoreceptor tyrosine activating motifs (ITAMs) in
the non-covalently associated Igα and Igβ heterodimers within
seconds. This leads to Syk kinase and PLCγ2 recruitment and
phosphorylation, Ca2+ release from endoplasmic reticulum and
MAPK activation. The stimulation of these many signaling path-
ways triggers the transcription factors NFAT, NFκB, and Fos, Jun,
and Ets [BCR signaling pathways reviewed in Ref. (28, 29)]. Sig-
naling and internalization of antigen are interdependent events.
Internalization through clathrin-coated pits is dependent on tyro-
sine phosphorylation of the heavy chain of clathrin by Src-family
kinases localized in lipid rafts (30). As antigen is brought in, sig-
naling continues as phosphorylated early kinases (Lyn and Syk)
remain associated to BCR until its trafficking to lysosomes; later
phosphorylated kinases such as Jnk, p-38, and Erk first associated
at the plasma membrane-early endosome interphase, continued
to accumulate in multivesicular bodies (MVB, 200–350 nm diam-
eter, the sites of antigen processing and loading onto MHC II).
Treatment with the dynamin inhibitor dynasore prevents clathrin-
mediated endocytosis and leads to hyperphosphorylation of Lyn,
Syk, Jnk, p-38, and Erk kinases, and hypophosporylation of Akt.
As a result, gene expression was dysregulated suggesting that
endocytosis is involved not only in antigen internalization but
is also required for signaling (31) presumably from endocytic
compartments themselves.
ANTIGEN PROCESSING AND LOADING TO MHCII
In the ER, newly synthesized MHC II αβ dimers associate with
the invariant chain (Ii), a chaperone that delivers MHC II to the
endocytic pathway. There, proteases such as Cathepsin S and L
stepwise cleave Ii to finally yield the class-II-associated invariant
chain peptide, CLIP, which remains associated with the peptide-
binding groove to prevent premature loading with peptides. MHC
II has been shown to localize to unique MIIC compartments, dis-
tinct from endosomes or lysosomes (32, 33). In B cells, it has
been shown that upon BCR ligation by F(ab)′2 specific for Ig,
MHC II dimers are redistributed to LAMP1 positive MVBs (34).
The distribution of Class II MHC products over MVB, lysosomes,
and other endosomal structures in response to BCR engagement
remains a matter of debate. Upon BCR ligation, BCR–antigen
complexes are brought into MHC II-rich compartments through
the endocytic pathway, and the heavy chain of BCR (35) as well
as Igα and Igβ (36) are ubiquitylated. Igβ is ubiquitylated at the
plasma membrane by the E3 ligase Itch, a process dispensable
for BCR–antigen internalization but required for sorting to com-
partments bearing the lysosomal marker LAMP1+ and antigen
presentation (36). BCR ubiquitylation also depends on Syk sig-
naling (37). In MHC II-rich compartments, H2/HLA-DM (DM),
removes CLIP peptide from MHC II to allow loading with anti-
genic peptides (Figure 2). In B cells, these processes are reversible
and the B cell phenotype, as assessed by surface markers, returns
to that of unstimulated cells after 24 h (34). DM not only removes
CLIP to permit binding of antigenic peptides to the peptide cleft
of MHC II, but also plays a role in selecting strong binders from
weak binders (38). B cells express the chaperone HLA-DO (DO), a
DM inhibitor (39) except for when MHC II are localized to acidic
compartments; this mode of inhibition ensures that only peptides
that are a result of proteolytic degradation of antigens internal-
ized through the BCR are loaded onto MHC II (38) (Figure 2).
As expected, DO expression is reduced in germinal center B cells,
which are competent APCs (40).
The actin cytoskeleton plays a role in antigen presentation by B
cells; its regulation is shared with components of the BCR pathway
such as Syk, Btk, and Vav (41). The actin motor myosin II pro-
tein also regulates MHC II trafficking and antigen presentation,
through Ii-dependent interaction with Class II MHC molecules
(42). As mentioned before, B cells polarize the microtubule-
organizing center and Class II MHC compartments toward the
point of first contact with antigen upon antigen binding, a step
required for normal B cell function. B cells maintain a polar-
ized antigen distribution upon division, which leads to unequal
partitioning of captured antigen over daughter cells: the mother
cell contains a full antigenic load while daughter cells are devoid
of antigen. This asymmetrical distribution of antigen leads to
unequal antigen presentation capabilities; antigen content corre-
lates with the ability to present antigen to CD4 T cells. However,
symmetrical division and antigen segregation do occur and the
diminishing presentation capabilities of daughter cells may also
derive from progressive dilution of antigen in cells that divided
symmetrically (43). Thus, the actin cytoskeleton plays essential
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FIGURE 2 | Events that lead to antigen uptake by the BCR, loading
onto MHC Class II and presentation to CD4T cells. BCR interacts with
soluble antigen, or antigen presented by follicular dendritic cells (FDC),
macrophages or dendritic cells at the immunological synapse (IS), leading
to signaling events (red arrow), antigen-BCR complex uptake and
translocation to multi-vesicular bodies (MVB). There, proteases cleave
antigen into peptides that are loaded onto MHC Class II; H2/HLA-DM (DM)
mediates the removal of the class II-associated peptide (CLIP) which
prevents MHC Class II premature loading. H2/HLA-DO (DO) regulates DM.
In these compartments, BCR signaling continues (red arrow). B cells also
recruit and secrete MHC II-lysosomes to the IS space in a polarized fashion,
lowering the pH and facilitating removal of antigen or proteolysis.
Peptide-MHC II complexes are then transported to the cell surface for
presentation to CD4 T cells.
roles not only in the initiation of the processes required for efficient
antigen uptake but also in loading onto MHC II for presentation
to CD4 T cells.
CONCLUDING REMARKS
B cells are programed to present antigen to T cells primarily
after BCR-mediated internalization of the antigen. The process
of antigen recognition through the BCR not only triggers dras-
tic changes in B cell gene expression profiling, but also affects
endocytic trafficking and surface molecule expression. These steps
require antigens that are sufficiently strong to exceed the threshold
required for activation. When this criterion is met, BCR clus-
ters, B cells expand in size, with concomitant enhanced diffusion
rates of the BCR to capture more antigens. B cells then contract,
internalize antigen, proteolyze it and present the resulting pep-
tides on Class II MHC products. How exactly these processes
are coordinated remains to be uncovered: is there a minimum
BCR signaling level required to internalize antigen, or regard-
less of the signal strength will any antigen bearing the epitope
be internalized? Is BCR crosslinking required for triggering gene
expression, internalization, and antigen presentation, or just for
a few of these processes? The valency of antigen and affinity
are essential determinants to fully activate these processes, but
which aspects of signaling and antigen presentation are directly
affected remain to be established. B cell survival requires tonic
signaling via the BCR, and activation triggers must therefore be
finely tuned to prevent activation by non-optimal BCR ligands
and autoantigens. A better understanding of how BCR recogni-
tion of antigen is tuned to control downstream processes and
outcomes of B cell activation will require additional BCR ani-
mal models with homogeneous B cell populations; these models
will enhance our knowledge for the rational design of therapies
aimed to boost B cell responses or control B cell malignancies and
autoimmunity.
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